BRKRP
Bruker Corporation
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Buy
+42/100
Last price
445.04
▼ 21.04 (4.51%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
466.08
Day high
458.87
Day low
437.31
Volume
3.35K
Market cap
—
P/E (TTM)
—
52W range
264.30 – 484.90
Trailing performance
Returnvs SPY
1W
-5.47%
-7.4%
1M
+3.09%
+1.9%
3M
+4.60%
+0.1%
6M
+52.83%
+34.6%
YTD
+21.60%
+7.3%
1Y
+48.84%
+32.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BRKRP open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
0
Total on file
Fundamentals
Market cap—
Enterprise value$69.53B
Revenue (TTM)$3.50B
Gross profit$1.70B
EBITDA$541.10M
Net income$-106.90M
EPS (TTM)—
Free cash flow$179.94M
Total cash$184.90M
Total debt$1.86B
Book value / share$15.63
Shares outstanding—
Float103.69M
Short % of float—
Dividend yield3.58%
Beta (5Y)1.22
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book28.47
EV / revenue19.87
EV / EBITDA128.50
Gross margin48.48%
Operating margin9.88%
Profit margin-2.04%
Return on equity-3.00%
Return on assets3.14%
Debt / equity76.16
Current ratio1.85
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $3.44B | $3.37B | $2.96B | $2.53B | +2.1% |
| Operating revenue | $3.44B | $3.37B | $2.96B | $2.53B | +2.1% |
| Cost of revenue | $1.86B | $1.72B | $1.45B | $1.23B | +8.3% |
| Gross profit | $1.58B | $1.65B | $1.51B | $1.31B | -4.4% |
| Research & development | $395.20M | $376.50M | $294.80M | $235.90M | +5.0% |
| Selling, general & admin | $946.50M | $893.80M | $729.40M | $607.40M | +5.9% |
| Total operating expense | $1.34B | $1.27B | $1.02B | $843.30M | +5.6% |
| Operating income | $236.00M | $379.20M | $489.10M | $462.40M | -37.8% |
| Net interest income | -$46.70M | -$38.60M | -$5.20M | -$12.00M | -21.0% |
| Pre-tax income | $22.00M | $206.90M | $544.20M | $413.90M | -89.4% |
| Tax provision | $29.30M | $91.40M | $117.70M | $116.40M | -67.9% |
| Net income | -$8.60M | $113.10M | $427.20M | $296.60M | -107.6% |
| Net income to common | -$22.50M | $113.10M | $427.20M | $296.60M | -119.9% |
| EBIT | $82.30M | $254.80M | $560.60M | $430.00M | -67.7% |
| EBITDA | $302.60M | $438.60M | $675.50M | $518.70M | -31.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $298.80M | $183.40M | $488.30M | $645.50M | +62.9% |
| Cash & short-term investments | $298.80M | $183.40M | $488.30M | $645.50M | +62.9% |
| Accounts receivable | $544.90M | $565.50M | $492.00M | $472.70M | -3.6% |
| Inventory | $1.09B | $1.07B | $968.30M | $800.10M | +2.5% |
| Total current assets | $2.21B | $2.05B | $2.16B | $2.11B | +7.8% |
| Property, plant & equipment | $910.60M | $814.80M | $691.40M | $538.20M | +11.8% |
| Goodwill & intangibles | $2.45B | $2.42B | $913.10M | $728.50M | +1.1% |
| Total assets | $6.24B | $5.81B | $4.25B | $3.61B | +7.5% |
| Total current liabilities | $1.28B | $1.28B | $1.20B | $914.30M | -0.2% |
| Current debt | $16.60M | $32.50M | $121.20M | $18.70M | -48.9% |
| Long-term debt | $1.85B | $2.06B | $1.16B | $1.20B | -10.2% |
| Total debt | $2.04B | $2.25B | $1.38B | $1.27B | -9.0% |
| Total liabilities | $3.73B | $3.99B | $2.84B | $2.48B | -6.5% |
| Retained earnings | $2.36B | $2.41B | $2.32B | $1.93B | -1.9% |
| Working capital | $933.30M | $771.90M | $962.10M | $1.20B | +20.9% |
| Net tangible assets | $9.20M | -$638.60M | $464.10M | $385.30M | +101.4% |
| Shares issued | 152.14M | 182.46M | 175.94M | 175.39M | -16.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$8.30M | $113.80M | $428.50M | $298.50M | -107.3% |
| Depreciation & amortisation | $220.30M | $183.80M | $114.90M | $88.70M | +19.9% |
| Stock-based compensation | $20.20M | $25.30M | $30.90M | $27.70M | -20.2% |
| Change in working capital | -$144.80M | -$118.80M | -$87.80M | -$144.10M | -21.9% |
| Operating cash flow | $134.10M | $251.30M | $350.10M | $274.40M | -46.6% |
| Capital expenditure | -$120.20M | -$115.30M | -$106.90M | -$129.20M | -4.2% |
| Investing cash flow | -$196.50M | -$1.76B | -$326.00M | -$251.60M | +88.8% |
| Share buybacks | -$10.00M | $0 | -$152.30M | -$263.10M | — |
| Dividends paid | -$32.90M | -$30.20M | -$29.40M | -$29.80M | -8.9% |
| Financing cash flow | $135.10M | $1.23B | -$193.40M | -$415.30M | -89.0% |
| Free cash flow | $13.90M | $136.00M | $243.20M | $145.20M | -89.8% |
| End cash position | $303.10M | $186.70M | $491.60M | $648.70M | +62.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $838.50M | $823.40M | $977.20M | $860.50M | $797.40M | +1.8% |
| Operating revenue | $838.50M | $823.40M | $977.20M | $860.50M | $797.40M | +1.8% |
| Cost of revenue | $422.50M | $443.60M | $528.00M | $481.10M | $439.50M | -4.8% |
| Gross profit | $416.00M | $379.80M | $449.20M | $379.40M | $357.90M | +9.5% |
| Research & development | $94.30M | $101.30M | $99.60M | $98.30M | $100.20M | -6.9% |
| Selling, general & admin | $238.90M | $242.10M | $247.20M | $242.50M | $231.40M | -1.3% |
| Total operating expense | $333.20M | $343.40M | $337.40M | $344.40M | $331.60M | -3.0% |
| Operating income | $82.80M | $36.40M | $111.80M | $35.00M | $26.30M | +127.5% |
| Net interest income | -$2.50M | -$4.30M | -$12.30M | -$12.50M | -$12.80M | +41.9% |
| Pre-tax income | -$40.70M | $21.90M | $68.20M | -$71.80M | $500.00K | -285.8% |
| Tax provision | $14.20M | $2.50M | $37.80M | -$14.10M | -$3.10M | +468.0% |
| Net income | -$52.00M | $14.40M | $26.00M | -$59.60M | $7.60M | -461.1% |
| Net income to common | -$62.90M | $3.50M | $14.90M | -$62.40M | $7.60M | -1,897.1% |
| EBIT | -$22.90M | $34.10M | $79.40M | -$51.50M | $16.20M | -167.2% |
| EBITDA | $35.10M | $92.40M | $137.50M | $4.20M | $72.30M | -62.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $184.90M | $133.40M | $298.80M | $293.10M | $92.00M | +38.6% |
| Cash & short-term investments | $222.50M | $133.40M | $298.80M | $293.10M | $92.00M | +66.8% |
| Accounts receivable | $545.90M | $542.70M | $544.90M | $550.90M | $522.60M | +0.6% |
| Inventory | $1.12B | $1.12B | $1.09B | $1.20B | $1.22B | -0.1% |
| Total current assets | $2.23B | $2.10B | $2.21B | $2.35B | $2.16B | +5.8% |
| Property, plant & equipment | $714.10M | $719.60M | $910.60M | $746.70M | $758.50M | -0.8% |
| Goodwill & intangibles | $2.30B | $2.48B | $2.45B | $2.47B | $2.62B | -7.2% |
| Total assets | $6.05B | $6.13B | $6.24B | $6.43B | $6.34B | -1.3% |
| Total current liabilities | $1.20B | $1.36B | $1.28B | $1.27B | $1.35B | -11.1% |
| Current debt | $10.10M | $8.40M | $16.60M | $24.30M | $55.70M | +20.2% |
| Long-term debt | $1.81B | $1.66B | $1.85B | $1.98B | $2.38B | +9.1% |
| Total debt | $1.82B | $1.67B | $2.04B | $2.01B | $2.44B | +9.2% |
| Total liabilities | $3.62B | $3.63B | $3.73B | $3.94B | $4.47B | -0.3% |
| Retained earnings | $2.29B | $2.36B | $2.36B | $2.35B | $2.42B | -3.0% |
| Shareholder equity | $2.38B | $2.45B | $2.46B | $2.43B | $1.80B | -2.8% |
| Working capital | $1.02B | $748.50M | $933.30M | $1.08B | $815.30M | +36.3% |
| Net tangible assets | $83.80M | -$26.20M | $9.20M | -$36.90M | -$814.80M | +419.8% |
| Shares issued | 152.35M | 152.22M | 152.14M | 182.92M | 182.70M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$50.90M | $15.70M | $29.20M | -$58.50M | $4.20M | — | -424.2% |
| Depreciation & amortisation | $58.00M | $58.30M | $58.10M | $55.70M | $56.10M | — | -0.5% |
| Change in working capital | -$196.90M | -$24.20M | $124.20M | -$118.00M | -$160.30M | — | -713.6% |
| Operating cash flow | -$77.40M | $71.20M | $229.80M | -$33.20M | -$127.50M | — | -208.7% |
| Capital expenditure | -$28.80M | -$24.20M | -$52.00M | -$20.90M | -$21.30M | — | -19.0% |
| Investing cash flow | -$25.30M | -$39.70M | -$55.50M | -$23.80M | -$91.10M | — | +36.3% |
| Share buybacks | — | $0 | $0 | $0 | $0 | -$10.00M | — |
| Dividends paid | -$18.50M | -$18.60M | -$17.60M | $0 | -$7.60M | — | +0.5% |
| Financing cash flow | $149.20M | -$204.90M | -$167.60M | $258.40M | $95.50M | — | +172.8% |
| Free cash flow | -$106.20M | $47.00M | $177.80M | -$54.10M | -$148.80M | — | -326.0% |
| End cash position | $189.10M | $137.60M | $303.10M | $297.30M | $96.20M | — | +37.4% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $865.29M | +0.6% |
| Next quarter | — | — | $1.03B | +5.2% |
| Current year | — | — | $3.56B | +3.5% |
| Next year | — | — | $3.70B | +4.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.00%
Held by institutions99.52%
Institutions holding51
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
461.90
-3.65% from price
SMA 20
444.96
+0.02% from price
SMA 50
436.02
+2.07% from price
SMA 100
426.81
+4.27% from price
SMA 200
375.84
+18.41% from price
EMA 12
456.37
-2.48% from price
EMA 26
447.67
-0.59% from price
EMA 50
438.30
+1.54% from price
RSI (14)
49.2
Neutral
MACD (12,26,9)
8.70
Hist -0.20
ATR (14)
15.55
3.49% of price
Realised vol 30D
52.4%
Annualised
Bollinger upper
498.37
20, 2σ
Bollinger lower
391.56
20, 2σ
50 / 200 cross
Golden
436.02 vs 375.84
Trend bias
Above 200
+18.41%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.11
More volatile than market
Correlation to SPY
0.29
Largely independent
Realised vol 30D
52.4%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-35.0%
Peak to trough
Max drawdown 5Y
-35.0%
Peak to trough
ATR 14
15.55
3.49% of price
Beta (reported)
1.22
5Y monthly, from filing
Short interest
Shares short
2.58K
Prior 5.36K
Change vs prior
-51.8%
Shorts covering
% of float
—
—
% of shares out
—
Against total outstanding
Days to cover
0.9
Liquid
Float
103.69M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate$15.94 / yr
Forward yield3.58%
5-year avg yield—
Payout ratio—
Ex-dividend dateAug 14, 2026
Next pay dateSep 1, 2026
Last split—
Split date—
Headlines
3 Cash-Producing Stocks We Steer Clear Of
StockStory · 27m ago
Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution
Business Wire · 23h ago
Are Options Traders Betting on a Big Move in Bruker Stock?
Zacks · 2d ago
1 Surging Stock to Target This Week and 2 We Question
StockStory · 2d ago
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel
Zacks · 5d ago
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
Business Wire · 9d ago
Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound
MarketBeat · 10d ago
Is Bruker (BRKR) Using Flagship Academic NMR Deals To Deepen Its High-End Moat?
Simply Wall St. · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.